Investor Relations

Investor Relations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms.

With three unique projects, all developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.

Investor Relations contact
Tara Heitner, CEO

Latest Press Release

Financial Calendar

Silent period Q4, 2020

Start date: 13 January 2021

End date: 12 February 2021

The year-end report will be published on 12 February 2021 and the silent period starts 13 January 2021.

Year-end Report 2020

Date: 12 February 2021